SOURCE: Burrill & Company
SAN FRANCISCO, CA--(Marketwire - Jan 7, 2013) - Burrill & Company is pleased to announce that effective January 15, 2013, Frederick Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, and Mary Tanner, formerly Senior Managing Director at both Lehman Brothers Inc. and Bear Stearns & Co., have joined Burrill & Company. Mr. Frank will be Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. Ms. Tanner will be Senior Managing Director of both Burrill & Company and Burrill Securities.
Life Sciences Partners, LLC, a financial advisory firm owned by Mr. Frank and Ms. Tanner, will be associated with Burrill & Company. Life Sciences Partners concentrates on strategy and financial advice to life sciences companies. Its activities complement Burrill & Company's investment banking and principal investing businesses.
Mr. Frank joined Peter J. Solomon Company in 2009 from Barclays Capital, where he was Vice Chairman. He began his investment banking career at Smith, Barney & Co. Inc. in 1958, where he attained the positions of Co-Head of Research, Vice President and a Director. Subsequently, he joined Lehman Brothers, Inc., in 1969, as a partner. At Lehman Brothers Inc., Mr. Frank provided investment banking services to numerous companies in the pharmaceutical, biotechnology, healthcare services, medical device, and nutraceutical industries, and was involved in hundreds of financings, strategic alliances, and merger and acquisition transactions in the global healthcare industry.
Mr. Frank's clients have included: Marion Laboratories, from leading the company's initial public offering to its acquisition of the pharmaceutical division of Dow Chemical, creating Marion Merrill Dow. Then with Ms. Tanner, he represented Marion Merrill Dow in creating its merger with Hoechst to form Hoechst Marion Roussel, Inc. Mr. Frank also represented Synthélabo in France in its acquisition by Sanofi. Mr. Frank represented Genentech commencing in 1995 with the purchase of a controlling interest by Roche and in its 1999 extension & modification.
Most recently, Mr. Frank advised CV Therapeutics Inc. in its $1.4 billion sale to Gilead Sciences Inc.; BioDuro LLC, a China-based company, in its sale to PPD, Inc.; TargeGen, Inc., in its sale to Sanofi-Aventis; CGI Pharmaceuticals, Inc. in its sale to Gilead Sciences, Inc. and OSI Pharmaceuticals Inc. in its sale to Astellas Pharma Inc.
Mr. Frank received an M.B.A. from Stanford University and a B.A. from Yale University. He is also a chartered financial analyst.
Ms. Tanner heads Life Sciences Partners, a company she founded to specialize in healthcare investment and strategic advisory work. Previously, she served as Senior Managing Director at Lehman Brothers Inc. and Bear Stearns & Co., and as a Managing Director of Peter J. Solomon Company. Ms. Tanner has devoted more than 25 years to the global healthcare industry. Her expertise includes the ethical pharmaceutical industry, biotechnology, diagnostics, medical devices, healthcare services, cosmetics and consumer medicine industries. In addition to her well-known work with large companies, Ms. Tanner specializes in domestic and cross-border transactions between large and small companies, including corporate partnering and minority investments.
Ms. Tanner's clients have included: Pfizer in its $60 billion acquisition of Pharmacia; Amgen in its $16 billion acquisition of Immunex; Rhône-Poulenc in its acquisition of Rorer; followed by Rhône-Poulenc Rorer in its acquisition of U.K. company Fisons; BASF/BASF Pharma, in its acquisition of U.K. company Boots Pharmaceuticals.
Ms. Tanner received a B.A. from Harvard University.
"We are pleased to have attracted two industry icons to our business of building, advising, banking, and investing in life science companies worldwide," says G. Steven Burrill, CEO of Burrill & Company, a global financial services firm focused on the life sciences industry.
"We are delighted to be associated with Burrill & Company. We have known Steve Burrill for more than 40 years, and I have been a member of Burrill & Company's Advisory Board since its inception," says Mr. Frank. "We have had a long and productive relationship with Burrill's people and we highly value the global scope of Burrill & Company in life sciences."
About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm's businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia. For more information visit: www.burrillandco.com.